10x Genomics (TXG) AI Stock Analysis

• Market Cap: $1.75B
• Dividend Yield: N/A
• Average Volume (3M): 3.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: 2.02%
• EPS Growth: 65.33%
• Country: US
• Employees: 1,306
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.28
• Shares Outstanding: 114,411,470
• 10 Day Avg. Volume: 3,557,571
• 30 Day Avg. Volume: 3,267,496
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 2.41
• Enterprise Value/Ebitda: -19.96
• 1Y Price Target: $14.91
• Price Target Upside: 6.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12

• Rating: 56 Neutral
• Price Target: $14.00 ▼(-0.21% Downside)

10x Genomics' stock score is primarily influenced by its financial performance and technical analysis. While the company shows potential with improving cash flow and positive market momentum, profitability challenges and a negative P/E ratio weigh heavily on its valuation. The technical indicators suggest potential for price appreciation, but the financial fundamentals and valuation concerns limit the overall score.

Positive Factors

Acquisition Strategy

The acquisition of Scale Biosciences strengthens 10x Genomics' leadership position in single cell technology.

Financial Performance

TXG reported revenue that was modestly ahead of expectations, aided by a pull-forward in China.

Product Adoption

Growing placements of Chromium and Single Cell reaction growth on strong adoption of recently launched products plus robust Spatial consumables growth are encouraging signs amidst challenging market environment.

Negative Factors

Guidance Withdrawal

10x Genomics withdrew its full-year guidance due to uncertain macroeconomic conditions and significant exposure to pressured end-markets.

Macroeconomic Challenges

The macro environment remains challenging with external headwinds affecting the biopharma end-market and causing uncertainty in purchasing tools for discovery research.

Revenue Challenges

A significant portion of TXG's revenue comes from the US academic market, which faces budget constraints affecting overall demand.

10x Genomics Business Overview & Revenue Model

Company Description

10x Genomics (TXG) is a biotechnology company specializing in genomic sequencing and analysis technologies that enable researchers to gain insights into complex biological systems. Founded in 2012 and headquartered in Pleasanton, California, the company operates primarily in the life sciences sector. Its core products include the Chromium System, which allows for high-throughput single-cell sequencing, and various reagents and software solutions designed for applications in genomics, transcriptomics, and epigenomics. 10x Genomics serves a diverse customer base including academic institutions, pharmaceutical companies, and biotechnology firms, facilitating advancements in precision medicine and personalized therapeutics.

How the Company Makes Money

10x Genomics generates revenue primarily through the sale of its genomic sequencing systems, consumables, and related software products. The company's revenue model is based on a combination of product sales and recurring revenue from consumables, which are used in conjunction with its systems. Key revenue streams include sales of the Chromium System, various reagents, and software licenses that support data analysis and interpretation. Additionally, 10x Genomics benefits from strategic partnerships with research institutions and pharmaceutical companies, enhancing its market reach and driving sales through collaborative research initiatives. The increasing demand for genomic research and personalized medicine further contributes to its earnings, as more organizations invest in advanced genomic technologies.

10x Genomics Financial Statement Overview

Summary

10x Genomics demonstrates strong gross margins and a solid equity structure, reflecting operational efficiency and financial stability. However, consistent net losses and negative profit margins highlight profitability challenges. The cash flow position has improved, signaling better cash management, but operational risks persist due to negative earnings.

Income Statement

The company exhibits a strong gross profit margin of around 68.8% TTM, indicating efficient cost management relative to revenue. However, the net profit margin is negative, reflecting ongoing losses due to high operating expenses. Revenue growth has been modest at 2.3% TTM, and the negative EBIT and EBITDA margins highlight profitability challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 78.2% TTM, signifying financial stability. The debt-to-equity ratio is low at 0.11, indicating low leverage. However, the return on equity is negative, reflecting consistent net losses which impact shareholder returns.

Cash Flow

The company has shown improvement in free cash flow, turning positive to $44.36M TTM from previous losses. The operating cash flow to net income ratio is negative, reflecting operational challenges. However, the free cash flow growth rate is notable, indicating better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	644.47M	610.78M	618.73M	516.41M	490.49M	298.85M
Gross Profit	447.88M	414.48M	409.31M	396.02M	416.40M	240.38M
EBITDA	-54.18M	-133.99M	-205.11M	-128.49M	-24.59M	-513.77M
Net Income	-84.60M	-182.63M	-255.10M	-166.00M	-58.22M	-542.73M
Balance Sheet
Total Assets	979.97M	918.64M	965.14M	1.03B	1.02B	929.34M
Cash, Cash Equivalents and Short-Term Investments	447.26M	393.40M	388.69M	429.98M	587.45M	663.60M
Total Debt	86.74M	82.61M	95.37M	95.18M	81.98M	62.98M
Total Liabilities	206.69M	208.50M	224.10M	223.24M	201.26M	190.27M
Stockholders Equity	773.28M	710.13M	741.04M	805.74M	817.57M	739.07M
Cash Flow
Free Cash Flow	56.88M	-5.73M	-64.72M	-165.27M	-122.65M	-256.29M
Operating Cash Flow	66.95M	6.66M	-15.20M	-33.61M	-21.37M	-217.90M
Investing Cash Flow	-58.04M	-32.63M	133.49M	-350.89M	-106.73M	-38.39M
Financing Cash Flow	8.62M	10.91M	13.67M	15.82M	35.30M	468.91M

10x Genomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXG, the sentiment is Positive. The current price of 14.03 is above the 20-day moving average (MA) of 13.31, above the 50-day MA of 12.68, and above the 200-day MA of 12.05, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 59.14 is Neutral, neither overbought nor oversold. The STOCH value of 88.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TXG.

10x Genomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WGS	69 Neutral	$3.50B	6,517.11	0.60%	―	48.70%	―
CERT	65 Neutral	$1.75B	220.04	0.76%	―	11.61%	―
TXG	56 Neutral	$1.75B	―	-11.30%	―	2.02%	65.33%
SOPH	52 Neutral	$228.42M	―	-74.09%	―	7.31%	-7.49%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
SDGR	50 Neutral	$1.44B	―	-44.40%	―	18.59%	10.96%
HCAT	46 Neutral	$235.05M	―	-28.42%	―	5.55%	-0.99%

10x Genomics Corporate Events

10x Genomics Elects Directors at Annual Meeting

On June 3, 2025, 10x Genomics held its annual stockholders’ meeting via webcast, with a quorum of approximately 87.7% of eligible votes. The meeting resulted in the election of two Class III directors for a three-year term and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TXG) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on 10x Genomics stock, see the TXG Stock Forecast page.

10x Genomics Settles Litigation with Bruker Corporation

On May 12, 2025, 10x Genomics, Inc. reached a settlement and licensing agreement with Bruker Corporation, resolving all global litigation and proceedings between the parties. This agreement follows a series of lawsuits initiated by 10x Genomics against NanoString Technologies, Inc., which were inherited by Bruker after acquiring certain NanoString assets in May 2024, and is expected to lead to the dismissal of all claims within five days of the agreement date.

The most recent analyst rating on (TXG) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on 10x Genomics stock, see the TXG Stock Forecast page.